NeuBase Therapeutics Inc (NBSE)
0.378
0.00 (0.00%)
USD |
NASDAQ |
May 14, 16:00
NeuBase Therapeutics Research and Development Expense (Quarterly): 0.3876M for Sept. 30, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | 0.3876M |
| June 30, 2023 | 1.284M |
| March 31, 2023 | 1.240M |
| December 31, 2022 | 1.351M |
| September 30, 2022 | 5.487M |
| June 30, 2022 | 4.757M |
| March 31, 2022 | 6.836M |
| December 31, 2021 | 4.369M |
| September 30, 2021 | 3.800M |
| June 30, 2021 | 5.369M |
| March 31, 2021 | 3.174M |
| December 31, 2020 | 2.020M |
| September 30, 2020 | 2.609M |
| June 30, 2020 | 1.493M |
| March 31, 2020 | 1.616M |
| December 31, 2019 | 1.228M |
| September 30, 2019 | 16.18M |
| June 30, 2019 | 0.0828M |
| March 31, 2019 | 0.0945M |
| December 31, 2018 | 0.058M |
| September 30, 2018 | 0.0769M |
| June 30, 2018 | 0.0526M |
| March 31, 2018 | 1.802M |
| December 31, 2017 | 2.388M |
| September 30, 2017 | 4.248M |
| Date | Value |
|---|---|
| June 30, 2017 | 2.233M |
| March 31, 2017 | 5.994M |
| December 31, 2016 | 4.931M |
| September 30, 2016 | 4.703M |
| June 30, 2016 | 5.638M |
| March 31, 2016 | 4.044M |
| December 31, 2015 | 2.076M |
| September 30, 2015 | 1.361M |
| June 30, 2015 | 1.497M |
| March 31, 2015 | 3.176M |
| December 31, 2014 | 2.806M |
| September 30, 2014 | 1.239M |
| June 30, 2014 | 1.153M |
| March 31, 2014 | 0.6079M |
| December 31, 2013 | 1.352M |
| September 30, 2013 | 1.325M |
| June 30, 2013 | 0.4163M |
| March 31, 2013 | 0.4338M |
| December 31, 2012 | 0.5785M |
| September 30, 2012 | 0.5853M |
| June 30, 2012 | 0.353M |
| March 31, 2012 | 0.3512M |
| December 31, 2011 | 0.3362M |
| September 30, 2011 | 0.0839M |
| June 30, 2011 | 0.121M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.0828M
Minimum
Jun 2019
16.18M
Maximum
Sep 2019
3.516M
Average
2.315M
Median
Research and Development Expense (Quarterly) Benchmarks
| Ampio Pharmaceuticals Inc | 1.242M |
| Stoke Therapeutics Inc | 22.37M |
| ABVC BioPharma Inc | 0.0722M |
| MAIA Biotechnology Inc | 3.717M |
| Aprea Therapeutics Inc | 2.046M |